Search Results - "Shurtleff, Amy C."

HSPA5 is an essential host factor for Ebola virus infection by Patrick Reid, St, Shurtleff, Amy C., Costantino, Julie A., Tritsch, Sarah R., Retterer, Cary, Spurgers, Kevin B., Bavari, Sina

“…•Targeting HSPA5 chaperone activity inhibits EBOV.•EBOV transcript and protein production is impaired in the absence of HSPA5.•Targeting HSPA5 in vivo protects…”
Get full text

Marburgvirus hijacks nrf2-dependent pathway by targeting nrf2-negative regulator keap1 by Page, Audrey, Volchkova, Valentina A, Reid, Saint Patrick, Mateo, Mathieu, Bagnaud-Baule, Audrey, Nemirov, Kirill, Shurtleff, Amy C, Lawrence, Philip, Reynard, Oliver, Ottmann, Michele, Lotteau, Vincent, Biswal, Shyam S, Thimmulappa, Rajesh K, Bavari, Sina, Volchkov, Viktor E

“…Marburg virus (MARV) has a high fatality rate in humans, causing hemorrhagic fever characterized by massive viral replication and dysregulated inflammation…”
Get full text

Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge by Konduru, Krishnamurthy, Shurtleff, Amy C, Bradfute, Steven B, Nakamura, Siham, Bavari, Sina, Kaplan, Gerardo

“…Ebola virus (EBOV), a member of the Filoviridae that can cause severe hemorrhagic fever in humans and nonhuman primates, poses a significant threat to the…”
Get full text

Evaluation of Ebola Virus Inhibitors for Drug Repurposing by Madrid, Peter B, Panchal, Rekha G, Warren, Travis K, Shurtleff, Amy C, Endsley, Aaron N, Green, Carol E, Kolokoltsov, Andrey, Davey, Robert, Manger, Ian D, Gilfillan, Lynne, Bavari, Sina, Tanga, Mary J

“…A systematic screen of FDA-approved drugs was performed to identify compounds with in vitro antiviral activities against Ebola virus (EBOV). Compounds active…”
Get full text

Advanced morpholino oligomers: A novel approach to antiviral therapy by Warren, Travis K., Shurtleff, Amy C., Bavari, Sina

“…► PMOs can be rapidly designed and produced in response to emergency medical needs. ► PMOs exhibit antiviral activity against a variety of viruses in in vivo…”
Get full text

Opportunities for Refinement of Non-Human Primate Vaccine Studies by Prescott, Mark J, Clark, Carolyn, Dowling, William E, Shurtleff, Amy C

“…Non-human primates (NHPs) are used extensively in the development of vaccines and therapeutics for human disease. High standards in the design, conduct, and…”
Get full text

Assessment of the potential for host-targeted iminosugars UV-4 and UV-5 activity against filovirus infections in vitro and in vivo by Warfield, Kelly L., Warren, Travis K., Qiu, Xiangguo, Wells, Jay, Mire, Chad E., Geisbert, Joan B., Stuthman, Kelly S., Garza, Nicole L., Van Tongeren, Sean A., Shurtleff, Amy C., Agans, Krystle N., Wong, Gary, Callahan, Michael V., Geisbert, Thomas W., Klose, Brennan, Ramstedt, Urban, Treston, Anthony M.

“…Iminosugars are host-directed antivirals with broad-spectrum activity. The iminosugar, N-butyl-deoxynojirimycin (NB-DNJ or Miglustat®), is used in humans for…”
Get full text

Development of a new vaccine for the prevention of Lassa fever by Geisbert, Thomas W, Jones, Steven, Fritz, Elizabeth A, Shurtleff, Amy C, Geisbert, Joan B, Liebscher, Ryan, Grolla, Allen, Ströher, Ute, Fernando, Lisa, Daddario, Kathleen M, Guttieri, Mary C, Mothé, Bianca R, Larsen, Tom, Hensley, Lisa E, Jahrling, Peter B, Feldmann, Heinz

“…Recent importation of Lassa fever into Germany, the Netherlands, the United Kingdom, and the United States by travelers on commercial airlines from Africa…”
Get full text

Pre-symptomatic diagnosis and treatment of filovirus diseases by Shurtleff, Amy C, Whitehouse, Chris A, Ward, Michael D, Cazares, Lisa H, Bavari, Sina

“…Filoviruses are virulent human pathogens which cause severe illness with high case fatality rates and for which there are no available FDA-approved vaccines or…”
Get full text

Validation of the Filovirus Plaque Assay for Use in Preclinical Studies by Shurtleff, Amy C, Bloomfield, Holly A, Mort, Shannon, Orr, Steven A, Audet, Brian, Whitaker, Thomas, Richards, Michelle J, Bavari, Sina

“…A plaque assay for quantitating filoviruses in virus stocks, prepared viral challenge inocula and samples from research animals has recently been fully…”
Get full text

A STAT-1 knockout mouse model for Machupo virus pathogenesis by Bradfute, Steven B, Stuthman, Kelly S, Shurtleff, Amy C, Bavari, Sina

“…Machupo virus (MACV), a member of the Arenaviridae, causes Bolivian hemorrhagic fever, with ~20% lethality in humans. The pathogenesis of MACV infection is…”
Get full text

Standardization of the filovirus plaque assay for use in preclinical studies by Shurtleff, Amy C, Biggins, Julia E, Keeney, Ashley E, Zumbrun, Elizabeth E, Bloomfield, Holly A, Kuehne, Ana, Audet, Jennifer L, Alfson, Kendra J, Griffiths, Anthony, Olinger, Gene G, Bavari, Sina

“…The filovirus plaque assay serves as the assay of choice to measure infectious virus in a cell culture, blood, or homogenized tissue sample. It has been in use…”
Get full text

High degree of correlation between Ebola virus BSL-4 neutralization assays and pseudotyped VSV BSL-2 fluorescence reduction neutralization test by Konduru, Krishnamurthy, Shurtleff, Amy C., Bavari, Sina, Kaplan, Gerardo

“…•Neutralization assay based on VSV construct containing the EBOV GP and the GFP gene.•GFP is expressed in infected cells.•EBOV neutralizing antibodies reduce…”
Get full text

The impact of regulations, safety considerations and physical limitations on research progress at maximum biocontainment by Shurtleff, Amy C, Garza, Nicole, Lackemeyer, Matthew, Carrion, Jr, Ricardo, Griffiths, Anthony, Patterson, Jean, Edwin, Samuel S, Bavari, Sina

“…We describe herein, limitations on research at biosafety level 4 (BSL-4) containment laboratories, with regard to biosecurity regulations, safety…”
Get full text

Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation by Cashman, Kathleen A, Broderick, Kate E, Wilkinson, Eric R, Shaia, Carl I, Bell, Todd M, Shurtleff, Amy C, Spik, Kristin W, Badger, Catherine V, Guttieri, Mary C, Sardesai, Niranjan Y, Schmaljohn, Connie S

“…Lassa virus (LASV) causes a severe, often fatal, hemorrhagic fever endemic to West Africa. Presently, there are no FDA-licensed medical countermeasures for…”
Get full text

Medical countermeasures against henipaviruses: a review and public health perspective by Gómez Román, Raúl, Tornieporth, Nadia, Cherian, Neil George, Shurtleff, Amy C, L’Azou Jackson, Maïna, Yeskey, Debra, Hacker, Adam, Mungai, Eric, Le, Tung Thanh

“…Henipaviruses, including Nipah virus, are regarded as pathogens of notable epidemic potential because of their high pathogenicity and the paucity of specific…”
Get full text

Animal models for ebolavirus countermeasures discovery: what defines a useful model? by Shurtleff, Amy C, Bavari, Sina

“…Ebolaviruses are highly pathogenic filoviruses, which cause disease in humans and nonhuman primates (NHP) in Africa. The Zaire ebolavirus outbreak in 2014,…”
Get more information

Vaccination of Rabbits with an Alkylated Toxoid Rapidly Elicits Potent Neutralizing Antibodies against Botulinum Neurotoxin Serotype B by Held, Daniel M, Shurtleff, Amy C, Fields, Scott, Green, Christopher, Fong, Julie, Jones, Russell G A, Sesardic, Dorothea, Buelow, Roland, Burke, Rae Lyn

“…Classifications Services CVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Recent successes in therapeutics for Ebola virus disease: no time for complacency by Iversen, Patrick L, Kane, Christopher D, Zeng, Xiankun, Panchal, Rekha G, Warren, Travis K, Radoshitzky, Sheli R, Kuhn, Jens H, Mudhasani, Rajini R, Cooper, Christopher L, Shurtleff, Amy C, Nasar, Farooq, Sunay, Melek ME, Duplantier, Allen J, Eaton, Brett P, Zumbrun, Elizabeth E, Bixler, Sandra L, Martin, Shannon, Meinig, J Matthew, Chiang, Chih-Yuan, Sanchez-Lockhart, Mariano, Palacios, Gustavo F, Kugelman, Jeffrey R, Martins, Karen A, Pitt, Margaret L, Crozier, Ian, Saunders, David L

“…The PALM trial in the Democratic Republic of the Congo identified a statistically significant survival benefit for two monoclonal antibody-based therapeutics…”
Get full text

A systematic screen of FDA-approved drugs for inhibitors of biological threat agents by Madrid, Peter B, Chopra, Sidharth, Manger, Ian D, Gilfillan, Lynne, Keepers, Tiffany R, Shurtleff, Amy C, Green, Carol E, Iyer, Lalitha V, Dilks, Holli Hutcheson, Davey, Robert A, Kolokoltsov, Andrey A, Carrion, Jr, Ricardo, Patterson, Jean L, Bavari, Sina, Panchal, Rekha G, Warren, Travis K, Wells, Jay B, Moos, Walter H, Burke, Raelyn L, Tanga, Mary J

“…The rapid development of effective medical countermeasures against potential biological threat agents is vital. Repurposing existing drugs that may have…”
Get full text